Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Anika Therapeutics (ANIK) over the last 16 years, with Sep 2025 value amounting to $58.0 million.

  • Anika Therapeutics' Cash & Equivalents fell 7.02% to $58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year decrease of 7.02%. This contributed to the annual value of $55.6 million for FY2024, which is 19.07% down from last year.
  • Anika Therapeutics' Cash & Equivalents amounted to $58.0 million in Q3 2025, which was up 9.07% from $53.2 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cash & Equivalents ranged from a high of $97.2 million in Q2 2021 and a low of $53.2 million during Q2 2025.
  • For the 3-year period, Anika Therapeutics' Cash & Equivalents averaged around $63.5 million, with its median value being $62.8 million (2024).
  • Per our database at Business Quant, Anika Therapeutics' Cash & Equivalents soared by 43.70% in 2021 and then decreased by 28.80% in 2023.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Cash & Equivalents stood at $94.4 million in 2021, then declined by 8.54% to $86.3 million in 2022, then declined by 20.37% to $68.7 million in 2023, then fell by 19.07% to $55.6 million in 2024, then dropped by 7.02% to $58.0 million in 2025.
  • Its Cash & Equivalents stands at $58.0 million for Q3 2025, versus $53.2 million for Q2 2025 and $53.4 million for Q1 2025.